Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Can a smart monitor help control diabetes? new study tests CGM in community clinics

NCT ID NCT07097415

Disease control Sponsor: Peking University Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jul 24, 2026 · Updated 2 times

Summary

This study tested whether using a continuous glucose monitor (CGM) helps adults with type 2 diabetes control their blood sugar better than traditional finger-prick testing. About 600 participants from two community health centers in China wore a CGM device for three 2-week periods over 24 weeks. The main goal was to see if their HbA1c levels improved. The study also looked at how easy or hard it is to use CGM in everyday community care.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
continuous glucose monitoring (CGM) device
What this could lead to
If successful, this could show that CGM helps people with type 2 diabetes better manage their blood sugar and improve quality of life in community settings.
What could go wrong
This is a completed pragmatic trial with 599 participants, but results may not apply to all populations. CGM devices can be costly and require training, and the study does not test a cure.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

599 people

The number who actually took part.

Started

Nov 2024

Finished

Nov 2025

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Age 18 years or older. ②A diagnosis of type 2 diabetes recorded in the electronic medical record for at least 1 year before screening. * A stable glucose-lowering treatment regimen, defined as no change in medication class during the 3 months before screening. * Residence in Yinzhou District and enrolment in the district resident health-record system. * Ability to provide written informed consent. ⑥For enrolment into the CGM-assisted management group, ability to operate the CGM mobile application independently or with assistance from a caregiver. Exclusion Criteria: * Pregnancy. * Type 1 diabetes, latent autoimmune diabetes in adults, or secondary diabetes. * Current or previous use of glucose-affecting agents other than prescribed glucose-lowering medication, including systemic glucocorticoids. * Estimated glomerular filtration rate below 60 mL/min/1·73 m². ⑤Alanine aminotransferase or aspartate aminotransferase greater than three times the upper limit of normal. * Active malignancy. ⑦Inability to provide informed consent.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Continuous glucose monitoring are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

type 2 diabetes mellitus

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Continuous glucose monitoring Type 2 diabetes (T2DM)

Contacts and locations

Locations

  • Fuming Street Community Health Service Center

    Ningbo, China

  • Qianhu Hospital

    Ningbo, Zhejiang, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.